Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Quintiles IMS Holdings Inc    Q

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
05/19/2017 05/22/2017 05/23/2017 05/24/2017 05/25/2017 Date
83.05(c) 83.54(c) 83.8(c) 84.22(c) 84.7 Last
1 122 290 555 819 767 577 631 807 2 399 963 Volume
-0.05% +0.59% +0.31% +0.50% +0.57% Change
More quotes
Financials ($)
Sales 2017 8 025 M
EBIT 2017 1 790 M
Net income 2017 536 M
Debt 2017 3 594 M
Yield 2017 -
Sales 2018 8 504 M
EBIT 2018 1 990 M
Net income 2018 691 M
Debt 2018 5 749 M
Yield 2018 -
P/E ratio 2017 37,43
P/E ratio 2018 29,32
EV / Sales2017 2,76x
EV / Sales2018 2,86x
Capitalization 18 532 M
More Financials
Company
Quintiles IMS Holdings, Inc. is a biotechnology company, which engages in healthcare development in the provision of professional services, information technology, and partnering solutions to the pharmaceutical services and healthcare industries.The company was founded by Dennis Gillings and Gary... 
More about the company
Surperformance© ratings of Quintiles IMS Holdings Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on QUINTILES IMS HOLDINGS INC
02:01p QUINTILES IMS : QuintilesIMS Announces Pricing of Secondary Public Offering
05/24 QUINTILES IMS : QuintilesIMS Announces Launch of Secondary Public Offering, Repu..
05/24 QUINTILES IMS HOLDINGS, INC. (NYSE : Q) Files An 8-K Other Events
05/24 QUINTILES IMS HOLDINGS, INC. : Other Events, Financial Statements and Exhibits (..
05/08 QUINTILES IMS : Management's Discussion and Analysis of Financial Condition and ..
05/08 QUINTILES IMS : Gains at quintiles ims
05/05 QUINTILESIMS INSTITUTE STUDY : U.S. Drug Spending Growth of 4.8 Percent in 2016
05/03 QUINTILES IMS HOLDINGS, INC. (NYSE : Q) Files An 8-K Results of Operations and F..
05/03 QUINTILES IMS HOLDINGS, INC. : Results of Operations and Financial Condition, Fi..
05/03 QUINTILESIMS : Reports First-Quarter 2017 Results and Raises Full-Year 2017 Adju..
More news
Sector news : Biotechnology & Medical Research - NEC
05/23 UK competition watchdog accuses Merck of obstructing biosimilars
05/22 Cross-border M&A between U.S. and European firms at 10 year high
05/22DJAMGEN : Another Gloomy Day for Amgen
05/09 Sanofi pegs U.S. drug price rises to below healthcare inflation
05/09DJVERTEX PHARMACEUTICALS INCORPORATED : Trump's Pick to Lead FDA Has Backing of Bi..
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
05:46p#VolumeRadar $Q QUINTILES IMS HOLDINGS INC #TradeIdeas via ?  
12:31aBRIEF-Quintiles IMS Holdings files for potential stock shelf  
12:24aQuintiles IMS Holdings $Q Getting Positive Media Coverage, Study Finds  
05/244,160 Shares in Quintiles IMS Holdings Inc $Q Acquired by ProVise Management .. 
05/244,668 Shares in Quintiles IMS Holdings Inc $Q Acquired by Private Advisor Gro.. 
More tweets
Qtime:62
News from SeekingAlpha
04:12a Tracking Larry Robbins's Glenview Capital Management Portfolio - Q1 2017 Upda..
05/10 Top Picks From The Sohn Investment Conference
05/03 Quintiles Transnational Holdings Inc. 2017 Q1 - Results - Earnings Call Slide..
05/03 Quintiles IMS Holdings (Q) Q1 2017 Results - Earnings Call Transcript
05/03 Quintiles Q1 revenues up 73%; updates guidance
Advertisement
Chart QUINTILES IMS HOLDINGS INC
Duration : Period :
Quintiles IMS Holdings Inc Technical Analysis Chart | Q | US74876Y1010 | 4-Traders
Full-screen chart
Technical analysis trends QUINTILES IMS HOL...
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 19
Average target price 86,6 $
Spread / Average Target 2,9%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Ari Bousbib Chairman, President & Chief Executive Officer
Michael R. McDonnell Chief Financial Officer & Executive Vice President
Karl Guenault Chief Information Officer & Senior Vice President
Jonathan J. Coslet Class I Director
Michael J. Evanisko Class I Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
QUINTILES IMS HOLDINGS..10.19%18 382
INCYTE CORPORATION37.73%27 528
LONZA GROUP AG23.08%15 234
CELLTRION, INC.--.--%10 254
SEATTLE GENETICS, INC.26.34%9 492
ALKERMES PLC3.83%8 934
More Results